Pharmacy Services Request Types

Similar documents
BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015

MedStar Medicare Choice Pharmacy Services

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

Pharmacy and Medical Guideline Updates

SPECIALTY PHARMACY Master Clinical Drug List

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

Brand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit

PA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*

Contents Please refer to Medical Policy I-31, Tocilizumab (Actemra) for additional information.

Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

Pharmacy Management Drug Policy

Medical Policies and Clinical Utilization Management Guidelines update

Medication Policy Manual. Policy No: dru408. Topic: Site of Care Review Date of Origin: July 10, 2015

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions

Injectable Drugs Requiring Pre-Service Approval

Aetna Better Health. Specialty Drug Program

Immune Modulating Drugs Prior Authorization Request Form

List of Designated High-Cost Drugs

Provider Newsletter. Table of Contents. Reimbursement Policy: Improve member medication regimen. Page 2

FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11)

In addition, certain medications that are used primarily for cosmetic purposes and prescription homeopathic products are maintained on the CRPA list.

Clinical UM Guidelines for Indiana, Kentucky, Missouri, Ohio and Wisconsin

Drug Infusion Site of Care Policy

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM

Original Policy Date

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description

Center for Evidence-based Policy

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Download full Test Bank for Focus on Nursing Pharmacology 6th Edition by Karch

Modular Program Report

Clinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.CPA.334 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.PHAR.258 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

MULTIPLE SCLEROSIS - REVIEW AND UPDATE

Medication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013

Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA

Medical policies update

Magellan Rx. A smarter approach to pharmacy benefits management

Medical Policy. MP Specialty Drugs. Related Policies Guidelines for Prior Authorization of Pharmacologic Therapies

High Risk Medications

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Special Notes Implementation Date by CO. State CG number CG title CG Category Original Current Version

The University of Mississippi Medical Center The University of Mississippi Health Care. Pharmacy and Therapeutics Committee Medication Use Evaluation

Carefirst.+.V Family of health care plans

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

State: Virginia. Clinical Guidelines Applicable for Virginia

Prescription Drug Benefit Rider V

2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA

Priority Health Medicare prior authorization form Fax completed form to: toll free, or

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Specialty Pharmacy Pipeline

Prescription Drug Benefit Rider

J-Code Trade Name Drug Name Required Medical Information

Anticipated Launches Q Q1 2019

Pharmacy Prior Authorization

See Important Reminder at the end of this policy for important regulatory and legal information.

2016 MDwise HIP Medical Services that Require Prior Authorization

Carelirst.+.V Family of health care plans

SCPS Specialty Pharmacy Protocols (CDTM Services Module)

See Important Reminder at the end of this policy for important regulatory and legal information.

Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

Drug Name (specify drug) Quantity Frequency Strength

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

2017 MDwise HIP Medical Services that Require Prior Authorization

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Orencia (abatacept) DRUG.00040

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin

Drug Class Review Targeted Immune Modulators

Choices. Disease modifying treatments. Read me

ACTEMRA. Cigna Medicare Rx (PDP) 2014 Cigna Medicare Rx Secure-Xtra Plan (PDP) Formulary. Products Affected Actemra. Prior Authorization Criteria

For all requests for Multiple Sclerosis Medications all of the following criteria must be met:

Billing for Infusion Services in an Outpatient Neurology Clinic. Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute

Immune Globulin. Prior Authorization

Updates to the Alberta Human Services Drug Benefit Supplement

Medicare Part C Medical Coverage Policy

Cost-Motivated Treatment Changes in Medicare Part B:

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

SUPPLEMENTARY INFORMATION

Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid

Prior Authorization. Drug Name (select from list of drugs shown) Gilenya (fingolomid) Quantity Frequency Strength. Physician Name:

Modular Program Report

Le Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono

Transcription:

FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare provider unless the member is currently inpatient. *Please note: most of the pharmacy Request Profiles display this alert in a pop-up box as soon as the provider chooses them in CareAffiliate: 1.**CRITICAL MESSAGE**: Use to request approval for medication that will be administered by a healthcare provider and billed as a medical claim. 2.**ATTENTION: YOU MUST ATTACH A SCANNED OR AN ELECTRONIC COPY OF THE MEDICAL RECORD TO THIS REQUEST** If you are using paper records and do not have a scanned copy, please STOP and go to www.hap.org/mrf to fill out a form and FAX to 313-664-5338 along with a copy of medical records. Please note this may delay processing. DRUG-Bone Health- DRUG-Bone Health-OFFICE admin DRUG-Erbitux or Vectibix- **For use to request authorization for osteoporosis and antiresorptive drugs when administered at an outpatient J0897 Prolia (denosumab) J0897 Xgeva (denosumab) **For use to request authorization for osteoporosis and antiresorptive (ex. Prolia/Xgeva) drugs when administered inoffice (i.e. provider's office is supplying the drug as a "buy J0897 Prolia (denosumab) and bill"; drug will NOT be billed to the patient's J0897 Xgeva (denosumab) **For use to request authorization for Erbitux or Vectibix, when administered at an outpatient infusion center (i.e. patient will go to an infusion center to receive the drug; drug will NOT be billed to the patient's J9055 Erbitux (cetuximab) J9303 Vectibix (panitumumab) used to treat colon & rectal cancer; other cancers you will get all drug request types if you by drug* *bone* *bone* *erbitux* *vectibix* DRUG-Erbitux or Vectibix- DRUG-General Request- HOME INFUSION admin **For use to request authorization for Erbitux or Vectibix, J9055 Erbitux (cetuximab) J9303 Vectibix (panitumumab) when administered in-office (i.e. provider's office is supplying the drug as a "buy and bill"; drug will NOT be billed used to treat colon & rectal cancer; other to the patient's cancers **DO NOT USE TO REQUEST: IVIG, Biologics to treat RA, CD/UC, Lupus, etc., Prolia, Xolair, Oncologics/Chemotherapy or any other drug/disease state that has a SPECIFIC Request Profile. Please review available choices under the name "DRUG-..."** This is for general Home Infusion requests where no other Request Type would apply Fabrazyme (agalsidase beta) for Fabry Disease *erbitux* *vectibix* *general* 1 last updated 9/11/15

DRUG-General Request- **DO NOT USE TO REQUEST: IVIG, Biologics to treat RA, CD/UC, Lupus, etc., Prolia, Xolair, Oncologics/Chemotherapy or any other drug/disease state that has a SPECIFIC Request Profile. Please review available choices under the name "DRUG-..."** This is for general Infusion Center requests where no other Request Type would apply Fabrazyme (agalsidase beta) for Fabry Disease *general* DRUG-General Request- **DO NOT USE TO REQUEST: IVIG, Biologics to treat RA, CD/UC, Lupus, etc., Prolia, Xolair, Oncologics/Chemotherapy or any other drug/disease state that has a SPECIFIC Request Profile. Please review available choices under the name "DRUG-..."** This is for general Office requests where no other Request Type would apply Fabrazyme (agalsidase beta) for Fabry Disease Testosterone implant (pellets) or injection *general* DRUG-GI Inflam Conditions- GI inflam conditions (CD, UC) when admin at an outpatient (CD=Crohn's Disease, UC=Ulcerative Colitis) *inflam* DRUG-GI Inflam Conditions- GI inflammatory conditions (ex. CD, UC), when administered inoffice (i.e. provider's office is supplying the drug as a "buy and bill"; drug will NOT be billed to the patient's (CD=Crohn's Disease, UC=Ulcerative Colitis) *inflam* DRUG-Hematologic conditions-infusion **Use: authorization for drugs to treat chronic hematologic conditions (ex. ITP) when administered at an outpatient (ITP=Idiopathic thrombocytopenic purpura; ahus=atypical Hemolytic-uremic syndrome) J2796 Nplate (romiplostim) J1300 Soliris (eculizumab) *hematologic* DRUG-Hematologic conditions- (ITP=Idiopathic thrombocytopenic purpura; chronic ahus=atypical Hemolytic-uremic syndrome) hematologic conditions (ex. ITP, ahus) when administered inoffice (i.e. provider's office is supplying the drug as a "buy and bill"; drug will NOT be billed to the patient's J2796 Nplate (romiplostim) J1300 Soliris (eculizumab) *hematologic* 2 last updated 9/11/15

DRUG-Hereditary Angioedema-INFUSION DRUG-Hereditary Angioedema- DRUG-IVIG-HOME admin hereditary angioedema when administered at an outpatient hereditary angioedema when administered in-office (i.e. provider's office is supplying the drug as a "buy and bill"; drug will NOT be billed to the patient's **For use to request authorization for IVIG (ex. Gammagard, Hizentra) when administered in-home (i.e. drug will be billed to home infusion J1744 Firazyr (icatibant) J1290 Kalbitor (ecallantide) J0598 Cinryze (complement C1 esterase C9445 Ruconest (conestat alfa) J0597 Berinert (complement C1 esterase J1744 Firazyr (icatibant) J1290 Kalbitor (ecallantide) J0598 Cinryze (complement C1 esterase C9445 Ruconest (conestat alfa) J0597 Berinert (complement C1 esterase J1569 Gammagard (immune globulin-- intravenous) J1559 Hizentra (immune globulin-- subcutaneous) *angioedema* *angioedema* *ivig* DRUG-IVIG-INFUSION **For use to request authorization for IVIG (ex. Gammagard, J1569 Gammagard (immune globulin-- Hizentra) when administered at an outpatient infusion intravenous) center (i.e. patient will go to an infusion center to receive the J1559 Hizentra (immune globulin-- drug; drug will NOT be billed to the patient's subcutaneous) *ivig* DRUG-IVIG- **For use to request authorization for IVIG (ex. Gammagard, J1569 Gammagard (immune globulin-- Hizentra) when administered in-office (i.e. provider's office is intravenous) supplying the drug as a "buy and bill"; drug will NOT be billed J1559 Hizentra (immune globulin-- to the patient's subcutaneous) *ivig* DRUG-Lupus-INFUSION lupus (ex. Benlysta), when administered at an outpatient infusion J0490 Benlysta (belimumab) center (i.e. patient will go to an infusion center to receive the drug; drug will NOT be billed to the patient's *lupus* DRUG-Lupus- lupus (ex. Benlysta), when administered in-office (i.e. provider's be billed to the patient's J0490 Benlysta (belimumab) *lupus* 3 last updated 9/11/15

DRUG-Multiple Sclerosis- multiple sclerosis (MS), when administered at an outpatient J9010 Lemtrada (alemtuzumab) use J3490 Ampyra (dalfampridine) J1826 Avoxex (interferon beta-1a) J1595 Copaxone (glatiramer) J1830 Extavia (interferon beta-1b) use J7599 Gilenya (fingolimod) J1826 Rebif (interferon beta-1a) *multiple* DRUG-Multiple Sclerosis- multiple sclerosis (MS), when administered in-office (i.e. provider's office is supplying the drug as a "buy and bill"; drug will NOT be billed to the patient's J9010 Lemtrada (alemtuzumab) use J3490 Ampyra (dalfampridine) J1826 Avoxex (interferon beta-1a) J1595 Copaxone (glatiramer) J1830 Extavia (interferon beta-1b) use J7599 Gilenya (fingolimod) J1826 Rebif (interferon beta-1a) *multiple* DRUG-Naltrexone inj.- **For use to request authorization for Naltrexone injection J2315 Vivitrol (naltrexone) (ex. Vivitrol) when administered at an outpatient infusion center (i.e. patient will go to an infusion center to receive the used to treat alcohol & narcotic drug drug; drug will NOT be billed to the patient's addiction *naltrexone* DRUG-Naltrexone inj.- **For use to request authorization for Naltrexone injection (ex. Vivitrol) when administered in-office (i.e. provider's be billed to the patient's J2315 Vivitrol (naltrexone) used to treat alcohol & narcotic drug addiction *naltrexone* DRUG-Oncology IV/SC- **For use to request authorization for intravenous (or SC) Oncologic drugs, when administered at an outpatient ORAL drugs would not be entered into CA; require a MRF (www.hap.org/mrf) *oncology* DRUG-Oncology IV/SC- **For use to request authorization for intravenous (or SC) Oncologic drugs, when administered in-office (i.e. provider's be billed to the patient's ORAL drugs would not be entered into CA; require a MRF (www.hap.org/mrf) *oncology* 4 last updated 9/11/15

DRUG-Plaque Psoriasis- plaque psoriasis, when administered at an outpatient infusion center (i.e. patient will go to an infusion center to receive the drug; drug will NOT be billed to the patient's J0215 Amevive (alefacept) J3357 Stelara (ustekinumab) *plaque* DRUG-Plaque Psoriasis- plaque psoriasis, when administered in-office (i.e. provider's office is supplying the drug as a "buy and bill"; drug will NOT be billed to the patient's J0215 Amevive (alefacept) J3357 Stelara (ustekinumab) *plaque* DRUG-Rheumatoid Conditions-INFUSION rheumatoid conditions, when administered at an outpatient J0129 Orencia (abatacept)--unless given J3262 Actemra (tocilizumab)--unless given J0129 subcutaneous Orencia (abatacept) J3262 subcutaneous Actembra (tocilizumab) *rheuma* DRUG-Rheumatoid Conditions-OFFICE administered rheumatoid conditions, when administered in-office (i.e. provider's office is supplying the drug as a "buy and bill"; drug will NOT be billed to the patient's J0129 Orencia (abatacept)--unless given J3262 Actemra (tocilizumab)--unless given J0129 subcutaneous Orencia (abatacept) J3262 subcutaneous Actembra (tocilizumab) *rheuma* DRUG-RSV prophylaxis- **For use to request authorization for RSV prophylaxis (ex. Synagis) when administered at an outpatient infusion center (i.e. patient will go to an infusion center to receive the drug; drug will NOT be billed to the patient's 90378 Synagis (Palivizumab IM injection) 90378 RSV-IGIM for IV infusion *rsv* 5 last updated 9/11/15

DRUG-RSV prophylaxis- DRUG-Sarcoidosis-INFUSION **For use to request authorization for RSV prophylaxis (ex. Synagis) when administered in-office (i.e. provider's office is 90378 Synagis (Palivizumab IM injection) supplying the drug as a "buy and bill"; drug will NOT be billed 90378 RSV-IGIM for IV infusion to the patient's sarcoidosis, when administered at an outpatient infusion center (i.e. patient will go to an infusion center to receive the drug; drug will NOT be billed to the patient's *rsv* *sarcoid* DRUG-Sarcoidosis-OFFICE admin DRUG-WRAP Member- HOME INFUSION DRUG-WRAP Member- OFFICE Admin DRUG-WRAP Member- OUTPATIENT HOSP Admin sarcoidosis, when administered in-office (i.e. provider's be billed to the patient's "**To request authorization for drugs for patients with HAP secondary coverage, when Medicare A+B are primary, when administered in-home (i.e. drug will be billed to HOME INFUSION " **To request authorization for drugs for patients with HAP secondary coverage, when Medicare A+B are primary, for inoffice administration (i.e. provider's office is supplying the drug as a "buy and bill")** **To request authorization for drugs for patients with HAP secondary coverage, when Medicare A+B are primary, when administered at an outpatient infusion center (i.e. patient will go to an infusion center to receive the drug)** home infusion administration for Medicare Wrap members (MC is primary/hap is secondary) office administration for Medicare Wrap members (MC is primary/hap is secondary) infusion center (OP hosp) administration for Medicare Wrap members (MC is primary/hap is secondary) *sarcoid* *wrap* *wrap* *wrap* DRUG-Xolair-INFUSION **For use to request authorization for Omalizumab (ex. Xolair) when administered at an outpatient infusion center (i.e. patient will go to an infusion center to receive the drug; drug will NOT be billed to the patient's J2357 Xolair (omalizumab) used to treat asthma *xolair* DRUG-Xolair- **For use to request authorization for Omalizumab (ex. J2357 Xolair (omalizumab) Xolair) when administered in-office (i.e. provider's office is supplying the drug as a "buy and bill"; drug will NOT be billed used to treat asthma to the patient's *xolair* 6 last updated 9/11/15